By Colin Kellaher

 

Gilead Sciences Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Yescarta cell therapy for certain B-cell lymphoma patients.

The Foster City, Calif., biopharmaceutical company said the recommendation covers adults with diffuse large B-cell lymphoma and high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

Gilead said it expects a decision from the European Commission, which generally follows the CHMP's advice, in the coming months, adding that approval would make Yescarta the first CAR T-cell therapy available in Europe for patients who don't respond to first-line treatment.

B-cell lymphoma makes up the vast majority of the blood cancer non-Hodgkin lymphoma.

Gilead last month said sales of Yescarta rose 66% in the second quarter to $295 million.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

September 16, 2022 07:39 ET (11:39 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Gilead Sciences Charts.